| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The primary targets of L-Ribulose are enzymes involved in carbohydrate metabolism, particularly L-arabinose isomerase and ribose-5-phosphate isomerase (Rpi). These enzymes catalyze the reversible isomerization between L-ribose and L-ribulose. L-Ribulose interacts with its target enzymes to undergo isomerization reactions. It is also a substrate for L-ribose isomerase, an enzyme that catalyzes the conversion between L-ribose and L-ribulose. As an endogenous metabolite, L-ribulose plays a role in cellular metabolism and is used in metabolic engineering applications, such as engineering yeast for xylose metabolism.
|
|---|---|
| ln Vitro |
In vitro, L-Ribulose is used as a substrate for studying enzyme kinetics and specificity. It is employed in assays to analyze the activity of L-ribose isomerase and ribose-5-phosphate isomerase. The compound is also used in metabolic engineering studies to improve xylose fermentation in yeast, where it serves as an intermediate in the pentose phosphate pathway. However, L-Ribulose does not have intrinsic pharmacological activity in the traditional sense; its "activity" is primarily as a metabolic substrate and a tool for studying carbohydrate metabolism.
|
| ln Vivo |
L-Ribulose is not a pharmacologically active compound in the traditional sense and therefore does not have in vivo activity as a drug. It is an endogenous metabolite that is naturally present in living organisms as part of normal carbohydrate metabolism. In research settings, L-ribulose may be administered to animals or used in metabolic studies to trace metabolic pathways or to study the effects of carbohydrate metabolism on physiology. However, specific in vivo pharmacological data are not applicable for this compound.
|
| Enzyme Assay |
In vitro enzyme assays for L-Ribulose typically involve measuring the activity of isomerase enzymes that use it as a substrate. For example, L-ribose isomerase activity is assayed by incubating the enzyme with L-ribulose and measuring the production of L-ribose. The reaction can be monitored using HPLC, colorimetric methods, or coupled enzyme assays. Similarly, ribose-5-phosphate isomerase activity can be assayed using L-ribulose as a substrate. These assays are used to characterize enzyme kinetics, determine substrate specificity, and screen for enzyme inhibitors or activators.
|
| Cell Assay |
Cellular assays for L-Ribulose are typically performed in the context of metabolic engineering or metabolic flux analysis. For example, yeast cells engineered for xylose metabolism are cultured in media containing L-ribulose, and the production of downstream metabolites is measured. The compound's effects on cellular metabolism can be assessed by measuring the levels of various metabolites, gene expression, or cell growth. These assays are used to study the metabolic pathways involving L-ribulose and to optimize metabolic engineering strategies for the production of biofuels or other valuable compounds.
|
| Animal Protocol |
In vivo animal studies with L-Ribulose are not typically performed for pharmacological purposes, as it is an endogenous metabolite rather than a drug. In research settings, labeled L-ribulose may be administered to animals in metabolic tracer studies to track the flow of carbon through metabolic pathways. However, specific in vivo protocols for L-ribulose administration are not detailed in the available literature. The compound's role as a metabolite means that it is not evaluated in traditional pharmacological in vivo models.
|
| ADME/Pharmacokinetics |
As an endogenous metabolite, L-Ribulose is a normal constituent of cellular metabolism and is not considered a xenobiotic. Therefore, pharmacokinetic parameters such as half-life, clearance, and bioavailability are not applicable in the traditional sense for a drug. The compound is a small, water-soluble sugar (molecular weight 150.13) that is metabolized through normal carbohydrate metabolic pathways. It is stable when stored as a powder at -20°C for up to 3 years and in solution at -80°C for up to 1 year.
|
| Toxicity/Toxicokinetics |
L-Ribulose is an endogenous metabolite and is not considered toxic in the context of normal cellular metabolism. It is a naturally occurring sugar that is involved in fundamental metabolic processes. In research applications, it is used as a substrate or metabolic intermediate and is not typically associated with toxicity. However, as with any chemical compound, high concentrations or prolonged exposure could potentially have metabolic effects. No specific toxicological data are reported in the available literature for this compound.
|
| References | |
| Additional Infomation |
L-ribulose is a type of ribulose. It plays a metabolic role in Escherichia coli. L-ribulose is present in or produced by E. coli (K12 strain, MG1655 strain). L-ribulose has also been reported in Daphnia pulex, and relevant data are available for reference.
L-Ribulose is an endogenous metabolite and a research-grade compound. It is not a drug and is not approved for clinical use. Its primary applications are in biochemistry, enzymology, and metabolic engineering. It is used as a substrate for studying isomerase enzymes, as a building block for the synthesis of rare sugars and L-nucleoside analogues, and as a tool for engineering yeast for xylose fermentation. It is also of interest as a chiral pool compound for organic synthesis. |
| Molecular Formula |
C5H10O5
|
|---|---|
| Molecular Weight |
150.13
|
| Exact Mass |
150.053
|
| CAS # |
2042-27-5
|
| PubChem CID |
644111
|
| Appearance |
Light yellow to brown liquid
|
| Density |
1.711g/cm3
|
| Boiling Point |
364.2ºC at 760mmHg
|
| Flash Point |
174.1ºC
|
| Vapour Pressure |
8.85E-07mmHg at 25°C
|
| Index of Refraction |
1.545
|
| LogP |
-2.6
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
113
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
OC[C@@H]([C@@H](C(CO)=O)O)O
|
| InChi Key |
ZAQJHHRNXZUBTE-UCORVYFPSA-N
|
| InChi Code |
InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h3,5-8,10H,1-2H2/t3-,5-/m0/s1
|
| Chemical Name |
(3S,4S)-1,3,4,5-tetrahydroxypentan-2-one
|
| Synonyms |
L-erythro-2-PentuloseRibulose, L- L-Erythro-pentuloseL-Ribulose L-Adonose
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6609 mL | 33.3045 mL | 66.6089 mL | |
| 5 mM | 1.3322 mL | 6.6609 mL | 13.3218 mL | |
| 10 mM | 0.6661 mL | 3.3304 mL | 6.6609 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
